NEW YORK, Oct. 7, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Ariad Pharmaceuticals, Inc. ("Ariad" or the "Company") (NASDAQ: ARIA). Such investors are advised to contact Peretz Bronstein or his investor relations analyst Yael Hurwitz at email@example.com or 212-697-6484.
The investigation concerns whether Ariad and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On October 6, 2016, The Street published a report called "How Ariad Pharma Used a Safety Problem to Jack Up a Cancer Drug's Price," in which it described the conditions the Company used to up its price for the leukemia drug Iclusig. The article continued to say that after the U.S. Food and Drug Administration temporarily pulled Iclusig from the market, it did allow Iclusig to go back on the market with a reduced recommended dose and more restricted approved use. Ariad then "embarked on a series of massive price increases" for its now-niche drug, "instead of reducing its price tag to reflect less benefit overall." Following this news, Ariad stock dropped $0.52 per share, or 3.75%, to close at $13.35 on October 6, 2016.
If you are aware of any facts relating to this investigation, or purchased shares Ariad, you can assist this investigation by visiting the firm's site: http://www.bgandg.com/aria. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484 or via email firstname.lastname@example.org. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-ariad-pharmaceuticals-inc-aria-300341307.html
SOURCE Bronstein, Gewirtz & Grossman, LLC